IC
RARE icon

Ikarian Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ikarian Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.53M Sell
165,617
-316,954
-66% -$7.87M 0.6% 50
2026
Q1 		$10.1M Buy
482,571
+469,900
+3,708% +$10.6M 0.82% 34
2025
Q4 		$291K Buy
+12,671
New +$417K 0.02% 148
2025
Q2 		– Sell
-216,989
Closed -$7.82M – 178
2025
Q1 		$7.86M Buy
216,989
+38,000
+21% +$1.58M 0.97% 18
2024
Q4 		$7.53M Sell
178,989
-11
-0% -$546 1.02% 24
2024
Q3 		$9.94M Buy
+179,000
New +$9.12M 1.39% 19
2023
Q4 		– Sell
-174,945
Closed -$6.24M – 167
2023
Q3 		$6.24M Buy
174,945
+53,287
+44% +$2.11M 0.75% 37
2023
Q2 		$5.61M Buy
+121,658
New +$5.64M 0.89% 36
2020
Q3 		– Sell
-2,313
Closed -$181K – 205
2020
Q2 		$181K Sell
2,313
-11,939
-84% -$790K 0.01% 150
2020
Q1 		$633K Sell
14,252
-35,748
-71% -$1.86M 0.05% 128
2019
Q4 		$2.14M Buy
+50,000
New +$2.06M 0.35% 63

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ikarian Capital's RARE Position: Q2 2026 in Review

Ikarian Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 66% in Q2 2026, selling an estimated $7.87M and leaving 165,617 shares worth $5.53M. The position accounts for 0.6% of the portfolio, ranked #50.

Ikarian Capital first reported a position in RARE in Q4 2019 and has held it in 11 quarters since. The position peaked at $10.1M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Ikarian Capital held 165,617 shares of Ultragenyx Pharmaceutical worth $5.53M as of Q2 2026.
  • Ikarian Capital sold 316,954 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $7.87M.
  • Ultragenyx Pharmaceutical made up 0.6% of Ikarian Capital's portfolio in Q2 2026, its #50 holding.
  • Ikarian Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 11 quarters since.
  • Ikarian Capital's Ultragenyx Pharmaceutical position peaked at $10.1M in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.